Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Phase 2
Completed
- Conditions
- Solid TumorsHigh Grade GliomasLung CancerHead and Neck CancerSarcomaRenal Cell CarcinomaBreast Cancer
- Interventions
- Drug: Fluciclatide Injection
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 70
- Registration Number
- NCT00918281
- Locations
- ๐บ๐ธ
101 Carnegie Center, Princeton, New Jersey, United States
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 213
- Registration Number
- NCT00908310
- Locations
- ๐บ๐ธ
GE Healthcare, Princeton, New Jersey, United States
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Phase 4
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT00878878
- Locations
- ๐บ๐ธ
ICON Development Solutions, Elliott City, Maryland, United States
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 471
- Registration Number
- NCT00785044
- Locations
- ๐บ๐ธ
GE Healthcare, Princeton, New Jersey, United States
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Phase 2
Completed
- Conditions
- Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 78
- Registration Number
- NCT00785759
- Locations
- ๐ณ๐ด
GE Healthcare, Oslo, Norway
Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- GE Healthcare
- Registration Number
- NCT00785694
- Locations
- ๐ซ๐ท
GE Healthcare Medical Diagnostics, Velizy Cedex, Morane Saulnier, France
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
Completed
- Conditions
- Coronary Artery Disease (CAD)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 885
- Registration Number
- NCT00783302
- Locations
- ๐บ๐ธ
GE Healthcare, Princeton, New Jersey, United States
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
Phase 4
Completed
- Conditions
- Echocardiography
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 1039
- Registration Number
- NCT00730964
- Locations
- ๐บ๐ธ
GE Healthcare, Princeton, New Jersey, United States
Evaluation Of The GE Monitor Product Line
Withdrawn
- Conditions
- RespirationECGTemperatureSpO2Non-invasive Blood Pressure
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GE Healthcare
- Registration Number
- NCT00730119
- Locations
- ๐บ๐ธ
GE Healthcare, Tampa, Florida, United States
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2009-11-09
- Lead Sponsor
- GE Healthcare
- Registration Number
- NCT00730444
- Locations
- ๐บ๐ธ
GE Healthcare, Princeton, New Jersey, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath